Adjunctive Treatments for Patients with Type 1 Diabetes Using Automated Insulin Delivery Systems. A Narrative Review.

This narrative review draws on a thin evidence base — the authors themselves describe the underlying data as limited, mixing small randomized and observational studies. Off-label GLP-1 use in type 1 diabetes is a live clinical question, and the early signal here is directionally encouraging on weight, insulin dose, and time in range. Larger and longer trials are needed before the safety picture, especially around ketoacidosis, can be considered settled.